vVARDIS Secures Apollo Investment, Reaches Unicorn Valuation
vVARDIS Holding AG, an emerging leader in dental medtech innovation, has announced a strategic minority investment from funds managed by Apollo. This development marks a significant milestone for the company as it accelerates its global growth strategy and expands the commercial reach of its groundbreaking non-invasive cavity treatment solutions. The investment positions vVARDIS among a select group of privately held European healthcare companies valued at over one billion dollars, reinforcing its status as a high-growth innovator in modern dentistry.
Founded by co-CEOs Dr. Haley Abivardi and Dr. Goly Abivardi, vVARDIS has carved out a unique niche by focusing on non-invasive, science-driven dental treatments. Despite the new investment, the founders will continue to retain a substantial majority stake in the company, maintaining strong leadership continuity and preserving the company’s long-term vision. This strategic partnership with Apollo is expected to provide the resources and expertise necessary to scale operations, penetrate new markets, and further advance the adoption of its flagship Curodont™ product line.
At the core of vVARDIS’ innovation is its proprietary Curodont™ technology, which represents a major breakthrough in the treatment of dental caries (tooth decay). Unlike traditional methods that rely on drilling and filling cavities, Curodont™ uses peptide-based formulations to stimulate the natural regeneration of tooth enamel. This approach addresses early-stage cavities in a non-invasive manner, eliminating the need for needles, drilling, or synthetic restorative materials. By enabling the formation of new crystalline mineral structures within the affected tooth area, the treatment effectively repairs damage while preserving the natural tooth structure.
The company’s flagship product, Curodont™ Repair Fluoride Plus, has demonstrated remarkable market traction, particularly in the United States. Since its launch more than two years ago, it has been used in the treatment of approximately three million teeth. Its rapid adoption underscores a growing demand among both dental professionals and patients for less invasive, more patient-friendly treatment options. Currently, the product is utilized in nearly 20 percent of general dental practices across the U.S., making it one of the fastest-growing innovations in the dental sector.
Industry experts and investors have recognized the significance of this technology. Representatives from Apollo emphasized that vVARDIS has successfully built a differentiated and compelling business model by introducing a new category in dental care. Backed by peer-reviewed clinical studies, the company’s solutions address a longstanding gap in dentistry: what to do when preventive measures fail but before invasive procedures become necessary. The investment from Apollo is expected to support the company’s continued expansion across key markets in North America and Europe, enabling broader access to its transformative treatment.
From the company’s perspective, the partnership represents more than just financial backing—it is a strategic alignment aimed at reshaping the future of dental care. Dr. Haley Abivardi highlighted that Curodont™ offers dentists a practical and efficient alternative to conventional cavity treatment. Its ease of use, combined with its non-invasive nature, allows dental professionals to deliver care that is both effective and comfortable for patients. The rapid adoption of the product reflects the urgent need for such solutions in everyday clinical practice.
Dr. Goly Abivardi further emphasized the company’s mission to bring a more medical and science-based approach to dentistry. By leveraging peptide technology, vVARDIS is moving away from traditional mechanical interventions and toward biologically driven treatments that align with the body’s natural healing processes. This approach not only improves patient outcomes but also reduces the environmental impact associated with conventional dental materials, positioning the company as a leader in sustainable healthcare innovation.
The broader context of this innovation is particularly compelling. Tooth decay remains the most prevalent non-communicable disease worldwide, affecting a vast majority of the global population. In the United States alone, nearly 90 percent of adults experience some form of dental caries during their lifetime. Beyond oral health, untreated cavities have been linked to a range of serious health conditions, including cardiovascular disease and other chronic illnesses. Studies have even indicated a measurable increase in all-cause mortality risk associated with poor oral health, underscoring the importance of early and effective intervention.
Global health authorities are increasingly recognizing the need for preventive and minimally invasive approaches to dental care. Recent guidelines from the World Health Organization advocate for early intervention strategies that reduce reliance on invasive procedures. vVARDIS’ technology aligns closely with these recommendations, positioning the company at the forefront of a global shift in dental treatment paradigms.
From a market perspective, the opportunity is substantial. The company estimates an addressable market exceeding $30 billion in the United States alone, driven by the widespread prevalence of tooth decay and the growing demand for advanced treatment options. With its proven technology, strong clinical validation, and expanding market presence, vVARDIS is well-positioned to capture a significant share of this opportunity.
The investment from Apollo is expected to accelerate several key initiatives, including scaling manufacturing capabilities, expanding distribution networks, and increasing awareness among dental professionals and patients. It will also support ongoing research and development efforts aimed at further enhancing the Curodont™ platform and exploring new applications of peptide-based dental therapies.
Despite the scale of the transaction, the financial terms have not been publicly disclosed. However, the strategic implications are clear: vVARDIS is entering a new phase of growth, backed by a major global investment firm and driven by a mission to transform how dental care is delivered.
In summary, vVARDIS’ partnership with Apollo represents a significant advancement in the evolution of dental medicine. By combining innovative science, strong leadership, and strategic investment, the company is poised to redefine cavity treatment on a global scale. Its non-invasive, biologically driven approach offers a compelling alternative to traditional methods, addressing both patient needs and broader healthcare challenges. As the company continues to expand its footprint and refine its technology, it stands at the forefront of a new era in dentistry—one that prioritizes preservation, regeneration, and patient-centered care.
About vVARDIS AG
vVARDIS is a disruptive Swiss healthcare company in the dental med-tech sector headquartered in Zug, Switzerland that offers groundbreaking, non-invasive solutions for dental professionals with the Curodont™ brand of products. Founded by Drs. Haley and Goly Abivardi, DMDs, sisters, internationally renowned dentists, innovators and self-made serial entrepreneurs, vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people’s lives, especially the underserved.
vVARDIS’ mission is to expand access to novel approaches that create new standards of care in dentistry with the purpose of improving oral health – the foundation for overall health. Backed by 25 years of research and more than 10 years of use in clinical practices globally, vVARDIS’ products and science are supported by more than 250 scientific publications, including meta-analysis, peer-reviewed and long-term peer-reviewed real-world evidence clinical studies, with a documented success rate above 90%. Curodont™ products are already presented in the lectures of renowned universities as a standard of care for the treatment of early decay. vVARDIS was awarded the 2026 Innovative Company of the Year and is a member of the World Economic Forum Innovator Communities
